LONDON, December 11, 2013
Treating abnormal bleeding - this new report shows you trends, R&D outlooks, and sales forecasts
Treatments for bleeding - what're their prospects? Visiongain's new report gives you predictions for drugs controlling those blood clotting diseases. Stay ahead then. You discover financial results, technologies, R&D trends, opportunities, and forecasted revenues.
So you see what's possible for treating haemophilia (hemophilia) and other blood-coagulation disorders. Avoid missing out. You get data and analysis for that industry and market, assessing outlooks. You find business analysis, progress, and potential gains.
Hear what lies ahead for those products, benefiting your work and influence. Read on, then, to explore those medicines and see what their future could be worth.
Forecasts and other information explaining lucrative possibilities for treatments
Our study reveals trade predictions to 2024 at overall world, submarket, product, and national level. For those therapies, you investigate where the money lies. Find potentials.
Besides revenue forecasting from 2013 to 2024, that new work shows historical findings, growth rates, and market shares. There you get feel for commercial outlooks and developments (R&D). You also gain an interview, 50 charts, and 78 tables.
Futures of medicines stopping and preventing haemorrhaging - data to help your work
Our study concludes that, from 2014, patients, healthcare providers, and pharma companies will gain from that medical and technological progress. Hear what's possible.
Find there how you can help your research, analyses, and decisions. Also save time. And discover how you could benefit your authority through better understanding the future.
So the following sections explain what you get in our new investigation.
Forecasting of that world market and its main segments - see what's likely to happen
What's that industry's potential? What're the secrets of its progress? Discover in our report overall world revenue to 2024 for pharmaceuticals controlling bleeding.
Also you see individual revenue predictions to 2024 for four therapeutic submarkets at world level:
• Haemophilia A
• Haemophilia B
• Related diseases (other coagulation factor deficiencies, grouped)
How will those markets expand? Which classes of therapy will generate most money? So you assess outlooks for sales growth, seeing where you can gain.
There you explore competition and rising sales. Also you assess products' futures.
Predicting of existing and expected therapies' revenues
Find sales outlooks for top brands, too, seeing how they compete and succeed. Our study shows you individual revenue forecasts to 2024 for 10 marketed products, including these:
You also get revenue predictions for five expected agents, including these:
There you find drugs and years with highest predicted sales rises. Also you examine competitors. You see what's happening, then, understanding challenges, competition, opportunities, and successes.
Our work also divides its overall prediction into geographical regions.
Healthcare in national markets - what outlooks for business?
In developed and developing countries, opportunities for providers of those products and technologies will occur from 2014 to 2024. See where and how, finding sales potentials.
Our analyses show you individual revenue forecasts to 2024 for 11 national markets:
• United States (US)
• Germany, France, UK, Italy, and Spain (EU5)
• Brazil, Russia, India, and China (BRIC nations).
There you find places with highest revenues and potential sales growth. Our work explains. You assess international prospects for modifying bleeding control, preventing excessive blood loss, also appraising needs and demands.
Explore, too, how that haematological technology benefits developers, producers, marketers, and sellers. Our work shows you, discussing issues.
Events and forces for developing, producing, marketing, and selling blood-stemming drugs
The report shows you issues and events affecting that industry from 2014, including these:
• Advances in understanding haemostasis and coagulation aiding science and product development
• Needle-free drug delivery and other innovations
• Synthetic purification processes and other novel techniques for making biologics and biosimilars
• Long-acting clotting factor therapy and recombinant coagulation factors
• Use of prophylactic schedules (prophylaxis) increasing
• Regulators, pricing, and other challenges - approvals, costs, and concerns.
There you explore political, economic, social, and technological questions, investigating outlooks for business. Discover what the future holds.
Examine, then, what stimulates and restrains players in that industry and affects results.
Companies and overall 2017 market value - find outlook for success
What happens next? From 2014 new treatments there and improving healthcare in rising countries encourage investments, medical advances, and higher revenues.
So our report predicts the world drugs market for preventing haemorrhages will generate $13.5bn in 2017. There, large medical firms and biopharma specialists can win. See how.
In particular, then, you explore activities and prospects of these companies:
• Novo Nordisk
• CSL Behring
R&D in that industry holds strengths, and from 2014 there will arise many opportunities. This decade onwards, then, patients, payers, and companies will benefit.
And you discover how that market can perform, staying ahead in knowledge.
Ways Bleeding Disorders: World Pharmaceutical Industry and Market 2014-2024 helps
In particular, our new investigation gives you these advantages:
• Revenues there to 2024 at world level, for 4 submarkets, and 15 products - assess outlooks for production, marketing, and sales
• Forecasts to 2024 for 11 national markets in the Americas, Europe, and Asia - examine developed and developing countries for potential revenues
• Prospects for established competitors, emerging companies, and new entrants - investigate portfolios, results, strategies, developmental activities, and successes.
Information found nowhere else, helping your searches, analyses, and decisions
Our new study gives independent analysis. There you receive competitive intelligence found only in our work, finding where progress and money lie. Explore commercial possibilities.
With that data you're less likely to fall behind in information or miss opportunity. Being free to choose, you find how you could save time and effort with our study, aiding your decisions.
You discover original insights then. So act now in advance of your rivals, also benefiting your authority.
Projections for that medical biotechnology - gain by trying our report
Our new report is for everyone investigating biological drugs (biologicals) and applied haematology. So find predictions you need. Avoid missing out - please order now.
Beijing Northland Biotech
Brazilian Ministry of Health
Canadian Haemophilia Society
Empresa Brasileira de Hemoderivadose Biotechnologia
European Medicines Agency (EMA)
Food and Drug Administration (US FDA)
Green Cross Corporation
Haemophilia Centres of England, Scotland, Northern Ireland or Wales
Haemophilia Treatment Centre Collaborative Network of China (HTCCNC)
Italian Association of Haemophilia Centres (AICE)
Johns Hopkins Medicine
National Health Service (NHS)
National Heart, Lung and Blood Institute
Shenyang Sunshine Pharmaceutical Co.
Spanish Haemophilia Society
Swedish Orphan Biovitrum
United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO)
US Food and Drug Administration (FDA)
World Federation of Haemophilia